BioVentures Investors

CoNextions Medical, Inc. manufactures tendon repair surgical healthcare equipment. It offers CoNextionsTR, a stainless steel and ultra-high molecular weight polyethylene implant that is designed for the surgically address tendon injuries. The company was founded in 2011 and is headquartered in Salt Lake City, Utah.

Pintex Pharmaceuticals, Inc. is a private pharmaceuticals company headquartered in Watertown, MA., that is engaged in the discovery and development of structure-based cancer therapeutics. In particular, the focus of Pintex's research is on the phosphate specific proline isomerase Pin1 enzyme and its key role in cancer. Pintex was founded in May 1999 by Dr. Kun Ping Lu, a Pew scholar at Harvard University, Dr. Walter Gilbert, a Nobel Prize winning professor at Harvard University and Dr. Janusz Sowadski, co-founder of Kinetix Pharmaceuticals, Inc., and a past recipient of the US Supercomputing Award for structure-based kinase inhibitor designs. Pintex was created in order to harness the many years of research and discovery performed and patented by researchers at the Salk Institute for Biological Studies and Harvard University.

Cylene Pharmaceuticals, Inc., a biotech pharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs that target nucleolus and kill cancer cells. It offers nucleolus targeting agents, which are small-molecule targeted cancer therapeutic agents for carcinoid/neuroendocrine tumors and pediatric brain tumors; and serine/threonine protein kinase inhibitors. The company also provides pre-clinical stage oral drug candidates. Cylene Pharmaceuticals, Inc. was founded in 1997 as Cyternex, Inc. and changed its name to Cylene Pharmaceuticals, Inc. in October 2003. The company is based in San Diego, California.

Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that address significant unmet medical needs. Hydra's ion channel drug discovery program is currently focused on channels implicated in pain, inflammation, and cardiovascular disease. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium, or potassium voltage-gated channels Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs. Hydra has raised significant financing from blue-chip investors since its inception. This prominent group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures.

Verax Biomedical, Incorporated, a medical products company, develops rapid tests for the detection of bacterial contaminants in blood cells and tissues for transplantation and cellular therapies. It offers platelet, red cell, and cell therapy pan genera detection (PGD) tests. The company was founded in 1999 and is based in Marlborough, Massachusetts.

Cardiosolutions, Inc. designs and develops a product for mitral regurgitation problem. The company develops Mitra-Spacer, a reversible implantable device that provides a sealing surface for the leaflets of the mitral valve, thereby reducing or eliminating mitral regurgitation. It serves patients of various ages who suffer from moderate to severe mitral regurgitation, including those who are currently in congestive heart failure. Cardiosolutions, Inc. was founded in 2005 and is based in West Bridgewater, Massachusetts.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.

Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that address significant unmet medical needs. Hydra's ion channel drug discovery program is currently focused on channels implicated in pain, inflammation, and cardiovascular disease. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium, or potassium voltage-gated channels Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs. Hydra has raised significant financing from blue-chip investors since its inception. This prominent group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures.

Pintex Pharmaceuticals, Inc. is a private pharmaceuticals company headquartered in Watertown, MA., that is engaged in the discovery and development of structure-based cancer therapeutics. In particular, the focus of Pintex's research is on the phosphate specific proline isomerase Pin1 enzyme and its key role in cancer. Pintex was founded in May 1999 by Dr. Kun Ping Lu, a Pew scholar at Harvard University, Dr. Walter Gilbert, a Nobel Prize winning professor at Harvard University and Dr. Janusz Sowadski, co-founder of Kinetix Pharmaceuticals, Inc., and a past recipient of the US Supercomputing Award for structure-based kinase inhibitor designs. Pintex was created in order to harness the many years of research and discovery performed and patented by researchers at the Salk Institute for Biological Studies and Harvard University.

Claros Diagnostics, Inc. is creating products to move in-vitro medical diagnostic tests out of the laboratory and into the hands of physicians and patients.

Ardais Corporation is a clinical genomics company, is dedicated to enhancing and accelerating biomedical research by introducing actual human disease into the pharmaceutical discovery research process. To achieve its goals, Ardais has incorporated multi-disciplinary scientific expertise into its operations, including pathology, molecular biology and genomics, statistical genomics, bioinformatics and medical informatics, as well as process management skills such as logistics, industrial engineering, and robotics. The result of this unique integration is a state-of-the-art, proprietary discovery platform that is dramatically transforming genomic research and leading the way to novel diagnostic and therapeutic solutions.

Verax Biomedical, Incorporated, a medical products company, develops rapid tests for the detection of bacterial contaminants in blood cells and tissues for transplantation and cellular therapies. It offers platelet, red cell, and cell therapy pan genera detection (PGD) tests. The company was founded in 1999 and is based in Marlborough, Massachusetts.

Angiolink Corporation offers EVS vascular closure system, an arterial stapling device for use in closing holes and punctures made in arteries in connection with the catheter-based surgical procedures, such as angioplasty and angiograms.

Claros Diagnostics, Inc. is creating products to move in-vitro medical diagnostic tests out of the laboratory and into the hands of physicians and patients.

Verax Biomedical, Incorporated, a medical products company, develops rapid tests for the detection of bacterial contaminants in blood cells and tissues for transplantation and cellular therapies. It offers platelet, red cell, and cell therapy pan genera detection (PGD) tests. The company was founded in 1999 and is based in Marlborough, Massachusetts.

Unified Information Devices, Inc. develops and manufactures laboratory animal identification devices and solutions. The products include implantable transponders, microchips, external transponders, readers, multiple tag programmers, and customized software. The company was incorporated in 2014 and is based in Lake Villa, Illinois.

HydroCision develops, manufactures, and markets fluidjet based surgical tools for minimally invasive spine surgery requirements. Its products include SpineJet HydroSurgery System that is used to ablate, cut, and remove targeted tissue for spinal procedures, Spinejet, water-based technology solutions for minimally invasive spine surgery requirements, SpineJet HydroDiscectomy Systems, which are used to remove tissue without the risk of thermal energy for minimally invasive discectomy procedures, and AlloJet, systems to prepare bone allografts. The company also provides customer care services. HydroCision, Inc. was formerly known as Surgijet Corporation and changed its name to HydroCision, Inc. in November 1996. The company was founded in 1994 and is headquartered in North Billerica, Massachusetts.

Endotronix is a developer of hemodynamic monitoring technologies to help detect worsening heart failure earlier than ever before. The company's platform includes a cloud-based disease management data system and outpatient hemodynamic management with a breakthrough implantable wireless pulmonary artery sensor for early detection of worsening heart failure. It was founded in 2007 and is based in Lisle, Illinois.

InSeal Medical Ltd. develops and manufactures percutaneous vascular closure devices. The company offers InSeal intravascular closure device, which supports the closure of 14-21Fr punctures in vessels of 6-10mm in diameter. Its devices are used for sealing of puncture sites following treatment involving a large bore sheath. The company is based in Caesarea, Israel. InSeal Medical Ltd. operates as a subsidiary of E-Pacing Inc.

Endotronix is a developer of hemodynamic monitoring technologies to help detect worsening heart failure earlier than ever before. The company's platform includes a cloud-based disease management data system and outpatient hemodynamic management with a breakthrough implantable wireless pulmonary artery sensor for early detection of worsening heart failure. It was founded in 2007 and is based in Lisle, Illinois.

Spirus Medical is a developer of advanced care medical devices for the gastrointestinal and cardiovascular markets. The company’s product portfolio includes the Endo-Ease  Discovery and Dexterity Steerable Introducer.

BRAINBox Solutions, Inc. develops and manufactures traumatic brain injury (TBI) tests for the diagnosis and prognosis of mild traumatic brain injury. It offers BRAINBox Solutions, a multi-modality approach that includes blood biomarker panels, neurocognitive testing, and point of care instruments. The company also provides quantitative test that combines injury-related blood protein biomarkers with computerized neurological assessments. BRAINBox Solutions, Inc. was founded in 2002 and is based in Richmond, Virginia.

Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that address significant unmet medical needs. Hydra's ion channel drug discovery program is currently focused on channels implicated in pain, inflammation, and cardiovascular disease. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium, or potassium voltage-gated channels Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs. Hydra has raised significant financing from blue-chip investors since its inception. This prominent group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures.

Cylene Pharmaceuticals, Inc., a biotech pharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs that target nucleolus and kill cancer cells. It offers nucleolus targeting agents, which are small-molecule targeted cancer therapeutic agents for carcinoid/neuroendocrine tumors and pediatric brain tumors; and serine/threonine protein kinase inhibitors. The company also provides pre-clinical stage oral drug candidates. Cylene Pharmaceuticals, Inc. was founded in 1997 as Cyternex, Inc. and changed its name to Cylene Pharmaceuticals, Inc. in October 2003. The company is based in San Diego, California.

Testing that is performed near or at the site of patient care with the result leading to possible change in the course of care of the patient. Testing that is performed outside a central laboratory environment, generally nearer to, or at the site of the patient. Also referred to as “near-patient” testing, or “point-of-need testing

Sciona provides gene-based personalized health and nutrition analysis and recommendations based on individual diet, lifestyle, and genetic profile. The company's Mycellf Program, which includes a diet and lifestyle questionnaire, makes recommendations for how individuals can make choices that benefit their long-term health. It also offers genetic testing products, which address personal wellness, fitness, and nutritional issues. The company was founded in 2000 and is headquartered in Aurora, Colorado.

Kanova is a biopharmaceutical firm.

Angiolink Corporation offers EVS vascular closure system, an arterial stapling device for use in closing holes and punctures made in arteries in connection with the catheter-based surgical procedures, such as angioplasty and angiograms.

Nano-Micro Technology is a hardware company, which provides uniformly sized nano- and microspheres.

Verax Biomedical, Incorporated, a medical products company, develops rapid tests for the detection of bacterial contaminants in blood cells and tissues for transplantation and cellular therapies. It offers platelet, red cell, and cell therapy pan genera detection (PGD) tests. The company was founded in 1999 and is based in Marlborough, Massachusetts.

Cylene Pharmaceuticals, Inc., a biotech pharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs that target nucleolus and kill cancer cells. It offers nucleolus targeting agents, which are small-molecule targeted cancer therapeutic agents for carcinoid/neuroendocrine tumors and pediatric brain tumors; and serine/threonine protein kinase inhibitors. The company also provides pre-clinical stage oral drug candidates. Cylene Pharmaceuticals, Inc. was founded in 1997 as Cyternex, Inc. and changed its name to Cylene Pharmaceuticals, Inc. in October 2003. The company is based in San Diego, California.

Verax Biomedical, Incorporated, a medical products company, develops rapid tests for the detection of bacterial contaminants in blood cells and tissues for transplantation and cellular therapies. It offers platelet, red cell, and cell therapy pan genera detection (PGD) tests. The company was founded in 1999 and is based in Marlborough, Massachusetts.

Provider of integrated data collection and data management solutions for clinical trials and drug safety

SonoMotion Inc. develops non-invasive solutions for kidney stone disease. It offers Break Wave, which fragments large kidney stones; and Stone Clear that helps clear the resulting stone fragments within 15 minutes in an office setting and also without general anesthesia or X-ray radiation. SonoMotion Inc. was founded in 2012 and is based in San Mateo, California.

Sciona provides gene-based personalized health and nutrition analysis and recommendations based on individual diet, lifestyle, and genetic profile. The company's Mycellf Program, which includes a diet and lifestyle questionnaire, makes recommendations for how individuals can make choices that benefit their long-term health. It also offers genetic testing products, which address personal wellness, fitness, and nutritional issues. The company was founded in 2000 and is headquartered in Aurora, Colorado.